CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As the US coast prepares for Hurricane Florence to make landfall, we have received importan...
In July, all 5 CTS laboratories will convert from the current Grifols Ultrio Plus NAT triplex assay ...
On September 23, 2019, the new CTS Laboratory Information System successfully implemented in Da...
Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today anno...
An exciting enhancement is implementing January 20, 2020 in our Special Testing laboratory as we mov...
We are very excited to launch our new website! Please take a few moments to click around and explore...